Literature DB >> 7768881

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma).

J M Lehmann1, L B Moore, T A Smith-Oliver, W O Wilkison, T M Willson, S A Kliewer.   

Abstract

Thiazolidinedione derivatives are antidiabetic agents that increase the insulin sensitivity of target tissues in animal models of non-insulin-dependent diabetes mellitus. In vitro, thiazolidinediones promote adipocyte differentiation of preadipocyte and mesenchymal stem cell lines; however, the molecular basis for this adipogenic effect has remained unclear. Here, we report that thiazolidinediones are potent and selective activators of peroxisome proliferator-activated receptor gamma (PPAR gamma), a member of the nuclear receptor superfamily recently shown to function in adipogenesis. The most potent of these agents, BRL49653, binds to PPAR gamma with a Kd of approximately 40 nM. Treatment of pluripotent C3H10T1/2 stem cells with BRL49653 results in efficient differentiation to adipocytes. These data are the first demonstration of a high affinity PPAR ligand and provide strong evidence that PPAR gamma is a molecular target for the adipogenic effects of thiazolidinediones. Furthermore, these data raise the intriguing possibility that PPAR gamma is a target for the therapeutic actions of this class of compounds.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7768881     DOI: 10.1074/jbc.270.22.12953

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  854 in total

Review 1.  LDL particle size: an important drug target?

Authors:  I Rajman; P I Eacho; P J Chowienczyk; J M Ritter
Journal:  Br J Clin Pharmacol       Date:  1999-08       Impact factor: 4.335

2.  Unraveling the mechanism of action of thiazolidinediones.

Authors:  C R Kahn; L Chen; S E Cohen
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

3.  Induction of Bach1 and ARA70 gene expression at an early stage of adipocyte differentiation of mouse 3T3-L1 cells.

Authors:  Makoto Nishizuka; Tomoko Tsuchiya; Tsutomu Nishihara; Masayoshi Imagawa
Journal:  Biochem J       Date:  2002-02-01       Impact factor: 3.857

Review 4.  Molecular mechanisms of adipocyte differentiation.

Authors:  Q Tong; G S Hotamisligil
Journal:  Rev Endocr Metab Disord       Date:  2001-10       Impact factor: 6.514

5.  Prostaglandin and PPAR control of immune cell function.

Authors:  Dino Rotondo; Jillian Davidson
Journal:  Immunology       Date:  2002-01       Impact factor: 7.397

6.  A dominant negative PPARgamma mutant shows altered cofactor recruitment and inhibits adipogenesis in 3T3-L1 cells.

Authors:  Y Park; B D Freedman; E J Lee; S Park; J L Jameson
Journal:  Diabetologia       Date:  2003-03-07       Impact factor: 10.122

7.  PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A.

Authors:  S Altiok; M Xu; B M Spiegelman
Journal:  Genes Dev       Date:  1997-08-01       Impact factor: 11.361

8.  Dominant-negative loss of PPARgamma function enhances smooth muscle cell proliferation, migration, and vascular remodeling.

Authors:  Dane Meredith; Manikandan Panchatcharam; Sumitra Miriyala; Yau-Sheng Tsai; Andrew J Morris; Nobuyo Maeda; George A Stouffer; Susan S Smyth
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-01-29       Impact factor: 8.311

9.  Effect of ciprofloxacin and ibuprofen on the in vitro metabolism of rosiglitazone and oral pharmacokinetics of rosiglitazone in healthy human volunteers.

Authors:  J N Suresh Kumar; Prameela Devi; Lakshmi Narasu; Ramesh Mullangi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2008 Oct-Dec       Impact factor: 2.441

10.  Effects of ethyl acetate extract of Kaempferia parviflora on brown adipose tissue.

Authors:  Hiroko Kobayashi; Emi Horiguchi-Babamoto; Mio Suzuki; Hiroko Makihara; Hiroshi Tomozawa; Masahito Tsubata; Tsutomu Shimada; Kiyoshi Sugiyama; Masaki Aburada
Journal:  J Nat Med       Date:  2015-09-19       Impact factor: 2.343

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.